Cingulate Inc. CING
4.26 USD +0.02 (+0.47%)
At closeNov 6, 2026, 4:26 PM EST
4.30 +0.04 +0.89%
After hours · Nov 6, 4:26 PM ET
4.23 Day range 4.34
3.16 52-week range 11.89
- YTD
- -1.84%
- 1 year
- +15.76%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…
benzinga.com Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9 Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.
benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $52 to $44.
benzinga.com Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14)…
benzinga.com Cingulate Joins Russell 3000E Index Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of…
benzinga.com Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts ORCL PT, Needham raises APLD PT, Morgan Stanley raises AAPL PT, BTIG raises NRIX PT, GLJ Research…
benzinga.com Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $52 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $55 to $52.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301.…- benzinga.com HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy and maintains $20 price target.
- benzinga.com Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.53) by 79.25 percent. This is a 10.38 percent increase over losses of $(1.06)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings page. Price targets and ratings altered for CING, WING, DEFT, FANG, PJT, DOCS, and AMZN.- benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $55 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $58 to $55.
benzinga.com Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14 Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $16 to $14.
benzinga.com What's Going On With Cingulate Stock Today? Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Cingulate Q4 EPS $(0.84) Misses $(0.61) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.61) by 37.03 percent. This is a 500 percent decrease over losses of $(0.14)…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Executive Chairman Of The Board But Will Continue To Serve As Chairman Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed on August 14, 2025, the…
- benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $62 to $58.
- benzinga.com Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16 Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $17 to $16.
- benzinga.com Cingulate Releases Phase 3 Trial Results For Its ADHD Treatment CTX-1301 Showing The Drug Met Its Primary Endpoints, Showing Dose-Dependent Improvements On ADHD Symptom And Severity Scales, And Demonstrated Effective Once-Daily Symptom Relief Using The Company's Precision Timed Release Technology Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
- benzinga.com Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual Meeting In Chicago Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
benzinga.com Roth Capital Maintains Buy on Cingulate, Raises Price Target to $17 Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $10 to $17.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Cingulate Announces That U.S. FDA Accepts For Review Its New Drug Application For CTx-1301, Its Lead ADHD Treatment Candidate For Children And Adults Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
- benzinga.com Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, Its Lead Drug Candidate For Treating ADHD Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation
- benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $62 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $61 to $62.
- benzinga.com Cingulate Q2 EPS $(1.09) Misses $(0.84) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.84) by 29.3 percent. This is a 80.07 percent increase over losses of $(5.47)…
- benzinga.com Cingulate Appoints Jennifer Callahan As Interim CEO; Names Jay Roberts Executive Chairman Jennifer Callahan, Chief Financial Officer, appointed Interim CEOBoard member, Jay Roberts appointed Executive ChairmanKANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:CING) The Board of…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $61 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $60 to $61.- benzinga.com Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $11 Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $12 to $11.
- benzinga.com Cingulate Receives Formal Pre-NDA Meeting Minutes From FDA For CTx-1301 In ADHD Details of the FDA's minutes include the following, all of which will be a matter of review during the approval process:The agency agreed to a post-NDA approval commitment of additional stability…
- benzinga.com Cingulate Q1 EPS $(1.04) Misses $(0.92) Estimate Cingulate (NASDAQ:CING) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.92) by 13.04 percent. This is a 85.56 percent increase over losses of $(7.20)…
- benzinga.com Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $60 Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $75 to $60.
- benzinga.com Cingulate Receives $3M Grant From Private Foundation To Accelerate Development Of Anxiety Asset CTx-2103; Beginning 6-Months After The After The First Commercial Sale Of CTx-2103, Payable At $500K Per Quarter, With A Maximum Cumulative Royalty Of $3.5M CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market
- benzinga.com Cingulate Announces Pre-NDA Meeting With FDA For Discussion Of New Drug Application For Lead ADHD Asset CTx-1301 KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform
- benzinga.com Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Why Meta Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents…